Teresa M. Tomchak
Teresa M. Tomchak
(604) 692-2704
(778) 785-2745
1055 West Hastings St, Suite 1700, The Guinness Tower, Vancouver, BC
Year called to bar: 2000 (BC); 2015 (ON)
Teresa has extensive experience in securities litigation and regulation. Teresa has been involved in numerous shareholder disputes, hostile takeover bids, proxy fights, contested plans of arrangement, and securities class actions. Teresa has represented clients during investigations and enforcement hearings before various provincial securities commissions and IIROC. Teresa is a co-author of CLE’s award-winning text, British Columbia Business Disputes. Teresa is recognized as Benchmark’s Top 100 Women in Litigation in Canada (2020–2022). She is also recognized as a Litigation Star by Benchmark Canada and was shortlisted for Canada’s Securities Litigator of the Year (2020–2022). She is recognized in The Canadian Legal Lexpert Directory (2019–2023) in the area of securities litigation; in Chambers Canada (2020–2023) in the area of securities litigation; and in The Best Lawyers in Canada (2018–2023) in the area of securities law.
Teresa M. Tomchak is a featured Leading Lawyer in:
Canadian Legal Lexpert Directory
Consistently Recommended
Read more about Teresa M. Tomchak in ...
ESG and Shareholder Rights: how activist investors are shaping the corporate world like never before
Farris' Teresa Tomchak explores current trends in shareholder activism both in Canada and abroad
Corporate civil wars: How activist shareholders are influencing Canada's companies
Farris' Teresa Tomchak details the players, proxies, and policies shaping shareholder activism today
The sale of Pure Multi-Family REIT LP (“Pure”) to Cortland Partners, LLC (“Cortland”) completed on September 27, 2019.
Intrexon Corporation (Intrexon) completed its acquisition of Okanagan Specialty Fruits Inc. (OSF) by way of statutory plan of arrangement pursuant to which a wholly-owned subsidiary of Intrexon acquired all the securities of OSF for US$41 million. OSF shareholders received US$31 million in Intrexon common stock and US$10 million in upfront cash, subject to certain escrow hold-back.
Tekmira Pharmaceuticals Corporation (“Tekmira”) completed a merger of equals with OnCore Biopharma, Inc. (“OnCore”) whereby OnCore merged with a wholly-owned subsidiary of Tekmira. As a result of the merger, stockholders of OnCore hold approximately fifty per cent (50%) of the total number of outstanding shares of capital stock of Tekmira. The implied market value of the combined company, based on the closing price of Tekmira common shares on the NASDAQ Global Market on January 9, 2015, was approximately USD$750 million and at time of closing USD$964 million.